FEV1 % predicted: absolute change from baseline · adults and children with cystic fibrosis
It is very uncertain whether short‐acting inhaled muscarinic antagonists changes change from baseline in FEV1 (% predicted) compared with placebo (very low certainty).
1 finding from 1 review
Quality of life  · adults and children with cystic fibrosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
FEV1 % predicted: absolute change from baseline · adults and children with cystic fibrosis
1 finding from 1 review
FVC (% predicted) Change from baseline · adults and children with cystic fibrosis
1 finding from 1 review
BHR: change in PC20 values · adults and children with cystic fibrosis
1 finding from 1 review
Change in exercise tolerance · adults and children with cystic fibrosis
1 finding from 1 review
Respiratory exacerbations: number of days on intravenous antibiotics for respiratory exacerbations · adults and children with cystic fibrosis
It is very uncertain whether summary of findings: inhaled corticosteroids changes respiratory exacerbations: number of days on intravenous antibiotics… compared with placebo (very low certainty).
1 finding from 1 review
Quality of life: Quality of Well Being score change from baseline · adults and children with cystic fibrosis
1 finding from 1 review
Adverse effects · adults and children with cystic fibrosis
1 finding from 1 review
FEV1 % predicted: absolute change from baseline · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
1 finding from 1 review
FVC (% predicted) Change from baseline · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
1 finding from 1 review
Pulmonary exacerbations · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Survival · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Antibiotic resistance · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Inhaled steroid dose · mild asthma
1 finding from 1 review
HRQoL ‐ all domains (change from baseline) Scale: age‐appropriate versions of the CFQ‐R questionnaire · children and young adults with CF
1 finding from 1 review
Lung function: FEV1 mL (percentage change from baseline) · children and young adults with CF
It is very uncertain whether summary of findings ‐ Inhaled mannitol plus dornase alfa changes lung function: FEV1mL (percentage change from baseline) compared with dornase alfa (very low certainty).
1 finding from 1 review
FEV1 % predicted · children and young adults with CF
The review found no eligible studies for this question.
1 finding from 1 review